With progress in genomics and proteomics research, the number of drug targets has blossomed, and companies are wading through the available targets searching for the most productive ones. Beyond Genomics Inc. believes that it can efficiently identify the best, or most relevant, targets using a dynamic approach to data analysis that it calls "systems biology."

The company's approach coordinates various sources of biologic data with a specific disease condition. Beyond Genomics collects and analyzes genomic, proteomic, and metabolite data from healthy and diseased humans and animals, and correlates patterns within and between these data points with disease.